The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Drug Delivery Nanoparticles in Skin Cancers
Open accessAbstract
Nanotechnology involves the engineering of functional systems at nanoscale, thus being attractive for disciplines ranging from materials science to biomedicine. One of the most active research areas of the nanotechnology is nanomedicine, which applies nanotechnology to highly specific medical interventions for prevention, diagnosis, and treatment of diseases, including cancer disease. Over the past two decades, the rapid developments in nanotechnology have allowed the incorporation of multiple therapeutic, sensing, and targeting agents into nanoparticles, for detection, prevention, and treatment of cancer diseases. Nanoparticles offer many advantages as drug carrier systems since they can improve the solubility of poorly water-soluble drugs, modify pharmacokinetics, increase drug half-life by reducing immunogenicity, improve bioavailability, and diminish drug metabolism. They can also enable a tunable release of therapeutic compounds and the simultaneous delivery of two or more drugs for combination therapy. In this review, we discuss the recent advances in the use of different types of nanoparticles for systemic and topical drug delivery in the treatment of skin cancer. In particular, the progress in the treatment with nanocarriers of basal cell carcinoma, squamous cell carcinoma, and melanoma has been reported.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags
Qian, X., Peng, X.-H., Ansari, D. O., Yin-Goen, Q., Chen, G. Z., Shin, D. M., Yang, L., Young, A. N., Wang, M. D., & Nie, S. (2008) · Nature Biotechnology · doi:10.1038/nbt1377 · Cited by 2,201
Micellar Nanocarriers: Pharmaceutical Perspectives
Torchilin, V. P. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9132-0 · Cited by 1,910 · cited 1×
“Specifically, the hydrophobic blocks form the core in order to minimize their exposure to aqueous surroundings, whereas the hydrophilic blocks form the corona-like shell to stabilize the core through direct contact with water [21].”
BackgroundMesoporous silica nanoparticles for drug delivery and biosensing applications
Slowing, I. I., Trewyn, B. G., Giri, S., & Lin, V. S. ‐. (2007) · Advanced Functional Materials · doi:10.1002/adfm.200601191 · Cited by 1,699 · cited 1×
“Moreover, great interest has been shown in nanoparticles delivery systems that can protect anticancer drugs against degradation and, combined with physical methods, significantly increase the tumor penetration of the drugs.”
BackgroundKojima, C., Kono, K., Maruyama, K., & Takagishi, T. (2000) · Bioconjugate Chemistry · doi:10.1021/bc0000583 · Cited by 663
Liposome application: problems and prospects.
Barenholz, Y. (2001) · Current Opinion in Colloid & Interface Science · doi:10.1016/s1359-0294(00)00090-x · Cited by 659
Activation of Stat3 in Human Melanoma Promotes Brain Metastasis
Xie, T.-X., Huang, F.-J., Aldape, K. D., Kang, S.-H., Liu, M., Gershenwald, J. E., Xie, K., Sawaya, R., & Huang, S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2674 · Cited by 393
Rancan, F., Papakostas, D., Hadam, S., Hackbarth, S., Delair, T., Primard, C., Verrier, B., Sterry, W., Blume-Peytavi, U., & Vogt, A. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9919-x · Cited by 249 · cited 1×
“tone (PCL) [90].”
Drug delivery using multifunctional dendrimers and hyperbranched polymers
Paleos, C. M., Tsiourvas, D., Sideratou, Z., & Tziveleka, L.-A. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2010.534981 · Cited by 156
Banciu, M., Metselaar, J. M., Schiffelers, R. M., & Storm, G. (2008) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2008.05.004 · Cited by 63
Colorectal cancer cell detection by 5-aminolaevulinic acid-loaded chitosan nano-particles
Yang, S.-J., Shieh, M.-J., Lin, F.-H., Lou, P.-J., Peng, C.-L., Wei, M.-F., Yao, C.-J., Lai, P.-S., & Young, T.-H. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.08.014 · Cited by 56
Cited by
A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems
Duan, Y., Dhar, A., Patel, C., Khimani, M., Neogi, S., Sharma, P., Siva Kumar, N., & Vekariya, R. L. (2020) · RSC Advances · doi:10.1039/d0ra03491f · Cited by 614
“22 Furthermore, since SLNs are based on nontoxic and non-irritating materials, they are ideal for use in topical formulations.”
BackgroundNanoparticles and nanofibers for topical drug delivery
Goyal, R., Macri, L. K., Kaplan, H. M., & Kohn, J. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.049 · Cited by 590
Hasan, N., Nadaf, A., Imran, M., Jiba, U., Sheikh, A., Almalki, W. H., Almujri, S. S., Mohammed, Y. H., Kesharwani, P., & Ahmad, F. J. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01854-3 · Cited by 322
Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies
Pizzimenti, S., Ribero, S., Cucci, M. A., Grattarola, M., Monge, C., Dianzani, C., Barrera, G., & Muzio, G. (2021) · Antioxidants · doi:10.3390/antiox10121942 · Cited by 79
Self-citation
Metadata
- Authors
- Dianzani, C., Zara, G. P., Maina, G., Pettazzoni, P., Pizzimenti, S., Rossi, F., Gigliotti, C. L., Ciamporcero, E. S., Daga, M., & Barrera, G.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-13
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W1970442695
- Cited by
- 184
- References
- 12
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.